Psoriatic arthritis
PsA · Immunology · 8 drugs · 2 indications
Inflammatory arthritis associated with psoriasis.
Competitive Landscape (8 drugs)
| Drug | Company | Mechanism | Modality | Route | Stage |
|---|
| Zasocitinib | — | TYK2 inhibitor | Small molecule | PO | PHASE3 |
| Bimzelx | UCB | IL-17A/F inhibitor | Antibody | SC | APPROVED |
| Cimzia | UCB | TNF inhibitor | Antibody | SC | APPROVED |
| Cosentyx | NVS | IL-17A inhibitor | Antibody | SC | APPROVED |
| Taltz | LLY | IL-17A inhibitor | Antibody | SC | APPROVED |
| Skyrizi | ABBV | IL-23 inhibitor | Biologic | IV/SC | APPROVED |
| Rinvoq | ABBV | JAK inhibitor | Small molecule | ORAL | APPROVED |
| Otezla | AMGN | PDE4 inhibitor (oral) | Small molecule | Oral | APPROVED |
Indications (2)
Active psoriatic arthritis
Upcoming Catalysts
Rinvoq - Vitiligo - FDA ApprovalREGULATORY
ABBV2026
Skyrizi - Psoriasis - H2H vs DeucravacitinibCLINICAL
ABBV2026
Rinvoq - GCA - FDA ApprovalREGULATORY
ABBV2026
Rinvoq - Alopecia Areata - Ph3 - Data (UP-AA)CLINICAL
ABBV2026
Rinvoq - HS - Ph3 - DataCLINICAL
ABBV2026
Rinvoq - SLE - Ph3 - DataCLINICAL
ABBV2026
Bimzelx - Commercial Momentum UpdatesCOMMERCIAL
UCB2026
Bimzelx vs Risankizumab - PsA - Head-to-Head DataCLINICAL
UCBH2 2026
Taltz + Zepbound - PsA/Obesity - FDA FilingREGULATORY
LLYH2 2026
Cosentyx - Biosimilar Competition TimelineCOMPETITIVE
NVSOngoing
Data from Supabase · Updated 2026-03-24